Celebrating 25 years of the Swiss Biotech Association

• 1998 Monoclonal antibodies Trastuzumab
  Herceptin, Roche, breast cancer
• 1998 Interferon beta-1a
  Rebif, Serono, multiple sclerosis
• 2001 Bosentan
  Tracleer, Actelion, pulmonary arterial hypertension (PAH)
• 2003 Kinase inhibitors Imatinib
  Gleevec, Novartis, cancer
• 2013 CRISPR-Cas9 gene editing
  CRISPR Therapeutics using technology to treat genetic diseases
• 2013 Humanized anti-CD20 monoclonal antibody Obinutuzumab
  Gazyva, Glycart/Roche, chronic lymphocytic leukaemia
• 2017 CAR-T cell therapy Tisagenlecleucel
  Kymriah, Novartis, leukaemia
• 2019 Humanized single chain antibody anti-VEGF Brolucizumab
  Beovu, Esbatech/Novartis, wet-AMD
• 2019 Gene therapy Onasemnogene abeparvovec-xioi
  Zolgensma, Novartis, paediatric spinal muscular atrophy (SMA)
• 2021 Aducanumab
  Aduhelm, Neuroimmune/Biogen, Alzheimer’s disease
• 2023 DDM Genomics and Multimodal platform
  SOPHiA GENETICS hits milestone of One Million Genomic Profiles analyzed by the SOPHiA DDM™ platform

Most of these highlights were achieved in international collaboration and benefit patients around the world. They do not represent a comprehensive list but rather a selection that emphasizes the diversity of modalities that have been developed over time and the broad range of medical needs they help to address.